Elmedical

Company Overview

Snapshot

Founded in April 2003 by Uzi Eshel and Jacob Lazarovitz, Elmedical operates with 1–10 employees. The company focuses on developing advanced thermal treatments for urological diseases. A significant milestone for the company was the publication of a phase I-II study on the efficacy and safety of its device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC, highlighting its commitment to clinical validation.

Business overview

Elmedical specializes in providing office-based systems for minimally invasive, non-ablative, high-temperature treatments (hyperthermia) for unmet urological diseases, specifically bladder cancer and prostatitis. Its core technology includes Bladder Wall Thermochemotherapy (BWT), which delivers chemotherapy at precise temperatures to the bladder lumen, and DuoThermia, designed for simultaneous hyperthermia treatment of the prostate and bladder. The company serves the healthcare industry, particularly urology providers, across geomarkets including Denmark, Italy, Spain, Austria, Switzerland, Greece, Germany, Croatia, and Turkey, operating within the Health Tech & Life Sciences sector.

Strategic signal

In January 2016, Elmedical's device for intravesical thermochemotherapy was featured in a phase I-II study published on PubMed, evaluating its efficacy and safety in non-grade 3 BCG recurrent NMIBC. This publication provides clinical validation for the company's technology, signaling to investors and innovation teams its potential for addressing significant medical needs in urology and its commitment to evidence-based solutions.

Company Intelligence Q&A

What is Elmedical's primary focus?

Elmedical focuses on developing and providing office-based systems for minimally invasive, non-ablative, high-temperature treatments (hyperthermia) for urological diseases such as bladder cancer and prostatitis.

Who founded Elmedical?

Elmedical was co-founded by Uzi Eshel and Jacob Lazarovitz in April 2003.

What are Elmedical's key products?

Elmedical offers products such as DuoThermia for chronic prostatitis/chronic pelvic pain syndrome and Bladder Wall Thermochemotherapy (BWT) for bladder cancer.

In which markets does Elmedical operate?

Elmedical operates in geomarkets including Denmark, Italy, Spain, Austria, Switzerland, Greece, Germany, Croatia, and Turkey.

Has Elmedical's technology been clinically validated?

Yes, in January 2016, a phase I-II study on the efficacy and safety of Elmedical's device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC was published on PubMed.